Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Psychiatry Reports
Erschienen in: Current Psychiatry Reports 1/2015

01.01.2015 | Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

Depression in HIV Infected Patients: a Review

verfasst von: Maria Giulia Nanni, Rosangela Caruso, Alex J. Mitchell, Elena Meggiolaro, Luigi Grassi

Erschienen in: Current Psychiatry Reports | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Depression is the most common neuropsychiatric complication in HIV-infected patients and may occur in all phases of the infection. Accurately, diagnosing major depressive disorder in the context of HIV is an ongoing challenge to clinicians and researchers, being complicated by the complex biological, psychological, and social factors associated with the HIV illness. Evidences exist to support the importance of improving the identification of depressive symptoms and their adequate treatment. Depression has long been recognized as a predictor of negative clinical outcomes in HIV-infected patients, such as reducing medication adherence, quality of life, and treatment outcome, and possibly worsening the progression of the illness and increasing mortality. By analyzing the most relevant studies (MEDLINE, EMBASE, PsycLit, Cochrane Library), the review discusses the epidemiology and the main clinical features of depression in HIV-infected patients, the causal pathways linking depression and HIV infection, the validity of screening tools, and the efficacy of different treatment approaches, including psychosocial interventions, psychopharmacology as well as HIV-specific health psychology health service models.
Literatur
1.
2.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. Plos Med. 2006;3(11):e442.2006.
3.
Dubè B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci. 2005;30(4):237–46.PubMedCentralPubMed
4.•
Owe-Larsson B, Säll L, Salamon E, Allgulander C. HIV infection and psychiatric illness. Afr J Psychiatry (Johannesbg). 2009;12(2):115–28. The review examines in a comprehensive way the prevalence and clinical features of the most common HIV-related neuropsychiatric disorders.
5.
Watkins CC, Pieper AA, Treisman GJ. Safety considerations in drug treatment of depression in HIV-positive patients: an updated review. Drug Saf. 2011;34(8):623–39.PubMed
6.•
Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158:725–30. This study used meta-analytic techniques to examine the relationship between depressive disorders and HIV infection and the risk that HIV-positive individuals have to develop depression compared with seronegative controls.PubMed
7.
Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.PubMed
8.
Nacher M, Adriouch L, Godard Sebillotte C, Hanf M, Vantilcke V, El Guedj M, et al. Predictive factors and incidence of anxiety and depression in a cohort of HIV-positive patients in French Guiana. AIDS Care. 2010;22(9):1086–92.PubMed
9.
Meade CS, Sikkema KJ. HIV risk behavior among adults with severe mental illness: a systematic review. Clin Psychol Rev. 2005;25(4):433–57. Epub 2005 Apr 12.PubMed
10.
Simoni JM, Safren SA, Manhart LE, Lyda K, Grossman CI, Rao D, et al. Challenges in addressing depression in HIV research: assessment, cultural context, and methods. AIDS Behav. 2011;15(2):376–88.PubMedCentralPubMed
11.
Phillips KD, Sowell RL, Rojas M, Tavakoli A, Fulk LJ, Hand GA. Physiological and psychological correlates of fatigue in HIV disease. Biol Res Nurs. 2004;6(1):59–74.PubMed
12.••
Schuster R, Bornovalova M, Hunt E. The influence of depression on the progression of HIV: direct and indirect effects. Behav Modif. 2012;36(2):123–45. This recent review describes a comprehensive multipath model, that explains the direct and indirect pathways leading from depression to HIV progression.PubMed
13.
Alciati A, Starace F, Scaramelli B, Campaniello M, Adriani B, Mellado C, et al. Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy? Eur Psychiatry. 2001;16(8):491–6.PubMed
14.•
Watkins CC, Treisman GJ. Neuropsychiatric complications of aging with HIV. J Neurovirol. 2012;18(4):277–90. This recent review well summarizes the current theories and research that link aging and HIV with psychiatric illnesses.PubMed
15.
Battegay M, Haerry DH, Fehr J, Staehelin C, Wandeler G, Elzi L. Psychosoziale aspekte bei der behandlung der hiv-infektion [in process citation]. Ther Umsch. 2014;71(8):509–13.PubMed
16.
Asch SM, Kilbourne AM, Gifford AL, Burnam MA, Turner B, Shapiro MF, et al. HCSUS consortium. Underdiagnosis of depression in HIV: who are we missing? J Gen Intern Med. 2003;18(6):450–60.PubMedCentralPubMed
17.
Pence BW, O’Donnell JK, Gaynes N. Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care. AIDS. 2012;26(5):656–8.PubMedCentralPubMed
18.
Mayston R, Kinyanda E, Chishinga N, Prince M, Patel V. Mental disorder and the outcome of HIV/AIDS in low-income and middle-income countries: a systematic review. AIDS. 2012;26 Suppl 2:S117–35.PubMed
19.
Carrico AW, Bangsberg DR, Weiser SD, Chartier M, Dilworth SE, Riley ED. Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons. AIDS. 2011;25(8):1113–8.PubMedCentralPubMed
20.
Sumari-de Boer IM, Sprangers MA, Prins JM, Nieuwkerk PT. HIV stigma and depressive symptoms are related to adherence and virological response to ART among immigrant and indigenous HIV infected patients. AIDS Behav. 2012;16:1681–9.PubMedCentralPubMed
21.
Katon W, Schulberg H. Epidemiology of depression in primary care. Gen Hosp Psychiatry. 1992;14(4):237–47.PubMed
22.
Sabin CA, Ryom L, De Wit S, Mocrof A, Phillips AN, Worm SW, et al. Association between immune depression and cardiovascular events in HIV infection. AIDS. 2013;27(17):2735–48.PubMed
23.
Mitchell AJ, Lord O, Malone D. Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: a meta-analysis. Br J Psychiatry. 2012;201(6):435–43.PubMed
24.
Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther. 2005;10(1):53–61.PubMed
25.
Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, Bartoli L, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45(5):394–402.PubMed
26.
Kleeberger CA, Buechner J, Patella F, Detels R, Riddler S, Godfrey R, et al. Changes in adherence to highly active antiretroviral medications in the multicenter AIDS cohort study. AIDS. 2004;18(4):683–8.PubMed
27.
Alciati A, Gallo L, Monforte AD, Brambilla F, Mellado C. Major depression-related immunological changes and combination antiretroviral therapy in HIV-seropositive patients. Hum Psychopharmacol. 2007;22(1):33–40.PubMed
28.
Leserman J. HIV disease progression: depression, stress and possible mechanisms. Biol Psychiatry. 2003;54(3):295–306.PubMed
29.
Leserman J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med. 2008;70(5):539–45.PubMed
30.
Coleman SM, Blashill AJ, Gandhi RT, Safren SA, Freudenreich O. Impact of integrated and measurement-based depression care: clinical experience in an HIV clinic. Psychosomatics. 2012;53(1):51–7.PubMed
31.
Tsai AC, Weiser SD, Peterson ML, Ragland K, Kushel MB, Bangsberg DR. A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV. Arch Gen Psychiatry. 2010;67(12):1282–90.PubMedCentralPubMed
32.
Chen WT, Shiu CS, Yang JP, Simoni JM, Fredriksen-Goldsen KI, Lee TS, et al. Antiretroviral therapy (ART) side effect impacted on quality of life, and depressive symptomatology: a mixed-method study. J AIDS Clin Res. 2013;4:218.PubMedCentralPubMed
33.
Chauhan VS, Chaudury S, Sudarsanan S, Srivastava K. Psychiatric morbidity in asymptomatic human immunodeficiency virus patients. Ind Psychiatry J. 2013;22(2):125–30.PubMedCentralPubMed
34.
Elenga N et al. Incidence and predictive factors of depression among patients with HIV infection in Guadeluope: 1988–2009. Int J of STD & AIDS. 2014;25(8):559–63.
35.••
Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression—a systematic review of interventions. Psychol Health Med. 2011;16(5):493–527. This review provides a comprehensive understanding of the most important treatment interventions (psychological, psychotropic, psychosocial, physical, HIV-specific health psychology interventions) proposed for depression in HIV infected patients.PubMed
36.
Gaynes BN, Pence BW, Eron Jr JJ, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008;70(4):505–11.PubMedCentralPubMed
37.
Eller LS, Rivero-Mendez M, Voss J, Chen WT, Chaiphibalsarisdi P, Iipinge S, et al. Depressive symptoms, self esteem, HIV symptom management self-efficacy and self-compassion in people living with HIV. AIDS Care. 2014;26(7):795–803.PubMed
38.
Kagee A, Martin L. Symptoms of depression and anxiety among a sample of South African patients living with HIV. AIDS Care. 2010;22(2):159–65.PubMed
39.
L’Akoa RM, Noubiap JJ, Fang Y, Ntone FE, Kuaban C. Prevalence and correlates of depressive symptoms in HIV-positive patients: a cross-sectional study among newly diagnosed patients in Yaoundé, Cameroon. BMC Psychiatry. 2013;13:228.PubMedCentralPubMed
40.
Ramirez-Avila L, Regan S, Giddy J, Chetty S, Ross D, Katz JN, et al. Depressive symptoms and their impact on health-seeking behaviors in newly-diagnosed HIV-infected patients in Durban, South Africa. AIDS Behav. 2012;16(8):2226–35.PubMedCentralPubMed
41.
Williams AB, Wang H, Li X, Chen J, Li L, Fennie K. Efficacy of an evidence-based ARV adherence intervention in China. AIDS Patient Care STDS. 2014;28(8):411–7. Epub 2014 Jul 21.PubMed
42.
Braganca M, Palha A. Depression and neurocognitive performance in Portuguese patients infected with HIV. AIDS Behav. 2011;15(8):1879–87.PubMed
43.
Talukdar A, Talukdar PS, Ghosal MK, Bal R, Ghosh P, Goswami DN. Evaluation of depression and coping skill among HIV-positive people in Kolkata, India. J Int Assoc Physicians AIDS Care (Chic). 2012;11(2):115–20.
44.
Dal-Bò MJ, Manoel AL, Filho AO, Silva BQ, Cardoso YS, Cortez J, Tramujas L, Silva RM. Depressive symptoms and associated factors among people with HIV/AIDS. J Int Assoc Provid AIDS Care, 2013.
45.
Grassi L. Risk of HIV infection in psychiatrically ill patients. AIDS Care. 1996;8(1):103–16.PubMed
46.
Carey MP, Carey KB, Maisto SA, Schroder KE, Vanable PA, Gordon CM. HIV risk behavior among psychiatric outpatients: association with psychiatric disorder, substance use disorder, and gender. J Nerv Ment Dis. 2004;192(4):289–96.PubMedCentralPubMed
47.
Rosenberg SD, Trumbetta SL, Mueser KT, Goodman LA, Osher FC, Vidaver RM, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health. 2001;91(1):31–7.PubMedCentralPubMed
48.
Wu ES, Rothbard A, Blank MB. Using psychiatric symptomatology to assess risk for HIV infection in individuals with severe mental illness. Community Ment Health J. 2011;47(6):672–8.PubMed
49.
Armstrong G, Jorm AF, Samson L, Joubert L, Nuken A, Singh S, et al. Association of depression, anxiety, and suicidal ideation with high-risk behaviors among men who inject drugs in Delhi, India. J Acquir Immune Defic Syndr. 2013;64(5):502–10.PubMed
50.
Richards D. Prevalence and clinical course of depression: a review. Clin Psychol Rev. 2011;31(7):117–25.
51.
Ickovics JR, Hamburger ME, Vlahov D, Shoenbaum EE, Schuman P, Boland RJ, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA. 2001;285(11):1466–74.PubMed
52.
Robertson K, Bayon C, Molina JM, McNamara P, Resch C, Muñoz-Moreno JA, et al. Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care. 2014;16:1–7.
53.
Morrison MF, Petitto JM, Ten Have T, Gettes DR, Chiappini MS, Weber AL, et al. Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry. 2002;159:789–96.PubMed
54.
McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol. 2010;67(6):699–714.PubMed
55.
Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care. 2009;21(8):976–83.PubMedCentralPubMed
56.
Omiya T, Yamazaki Y, Shimada M, Ikeda K, Ishiuchi-Ishitani S, Tsuno YS, et al. Mental health of patients with human immunodeficiency virus in Japan: a comparative analysis of employed and unemployed patients. AIDS Care. 2014;26(11):1370–8. Epub 2014 May 20.PubMed
57.
Peen J, Schoevers RA, Beekman AT, Dekker J. The current status of urban–rural differences in psychiatric disorders. Acta Psychiatr Scand. 2010;121:84–93.PubMed
58.
Hinnen C, Schreuder I, Jong E, van Duijn M, Dahmen R, van Gorp EC. The contribution of adult attachment and perceived social support to depressive symptoms in patients with HIV. AIDS Care. 2012;24(12):1535–42. Epub 2012 Apr 24.PubMed
59.
Talukdar A, Ghosal MK, Sanyal D, Talukdar PS, Guha P, Guha SK, et al. Determinants of quality of life in HIV-infected patients receiving highly active antiretroviral treatment at a medical college ART center in Kolkata, India. J Int Assoc Provid AIDS Care. 2013;12(4):284–90.PubMed
60.••
Del Guerra FB, Fonseca JLI, Figueiredo VM, Ziff EB, Konkiewitz EC. Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotropic pathways. J Neurovirol. 2013;19:314–27. This is a very recent review that gives a comprehensive understanding regarding the role of neuroendocrine, immunoinflammatory and monoaminergic mechanisms in predisposing HIV-positive patients to develop depression.PubMed
61.
Kaul M, Lipton SA. Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J Neuroimmune Pharmacol. 2006;1(2):138–51.PubMed
62.
Gendelman HE, Lipton SA, Tardieu M, Bukrinsky MI, Nottet HS. The neuropathogenesis of HIV-1 infection. J Leukoc Biol. 1994;56(3):389–98.PubMed
63.
Lawrence DM, Durham LC, Scwartz L, Seth P, Maric D, Major EO. Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol. 2004;78(14):7319–28.PubMedCentralPubMed
64.
Leonard BE. The concept of depression as a dysfunction of the immune system. Curr Immunol Rev. 2010;6(3):205–12.PubMedCentralPubMed
65.
Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurosurg Psychiatry. 2012;83(5):495–502.
66.
Poudel-Tandukar K, Bertone-Johnson ER, Palmer PH, Poudel KC. C-reactive protein and depression in persons with human immunodeficiency virus infection: the positive living with HIV (POLSH) study. Brain Behav Immun. 2014.
67.
Danzter R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.
68.
Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214(2):231–41.PubMed
69.
Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiatry. 2010;9(3):155–61.PubMedCentralPubMed
70.
Readler TJ. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry. 2011;24(6):519–25.
71.
Capuron L, Pagnosi G, Demetrashvili MF, Lawson DH, Fornwalt FB, Woolwine B, et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology. 2007;32(11):2384–92.PubMed
72.
Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD. Peripheral inflammation is associated with substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry. 2008;63(11):1022–9. Epub 2008 Feb 1.PubMedCentralPubMed
73.
Barack O, Goshen I, Ben-Hur T, Weidenfelt J, Taylor AN, Yirmiya R. Involvement of brain cytokines in the neurobehavioral disturbances induced by HIV-1 glycoprotein 120. Brain Res. 2002;933(2):98–108.
74.
Lawson MA, Kelley KW, Dantzer R. Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2,3-dioxygenase expression: a possible mechanism for AIDS comorbid depression. Brain Behav Immun. 2011;25(8):1569–75. Epub 2011 May 17.PubMedCentralPubMed
75.
Danzter R, O’Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011;36(3):426–36. Epub 2010 Oct 30.
76.•
Gutiérrez F, García L, Padilla S, Alvarez D, Moreno S, Navarro G, et al. Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs. HIV Med. 2014;15(4):213–23. This very recent study characterizes depression in a large sample of newly diagnosed HIV-infected patients and determines the effect of antiretroviral therapy (ART), on its incidence, investigate whether efavirenz use was associated with a higher risk, compared with non-efavirenz-containing regimens.PubMed
77.
Zhang L, Yang D, Zhao HX, Han N, Xiao J, Chen YF, et al. Assessment on depressive status and the therapeutic effects of highly active antiretroviral therapy among anti-HIV-1(+) population. Zhonghua Liu Xing Bing Xue Za Zhi. 2013;34(5):461–3.PubMed
78.
Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009;190:S54–60.PubMed
79.
Golub SA, Gamarel KE, Rendina HJ. Loss and growth: identity processes with distinct and complementary impacts on well-being among those living with chronic illness. Psychol Health Med. 2013;19(5):572–9. Epub 2013 Nov 15.PubMed
80.
Schuster RM, Gonzalez R. Substance abuse, hepatitis C, and aging in HIV: common cofactors that contribute to neurobehavioral disturbances. Neurobehav HIV Med. 2012;2012(4):15–34.PubMedCentralPubMed
81.
Grassi L, Righi R, Makoui S, Sighinolfi L, Ferri S, Ghinelli F. Illness behaviour, emotional stress and psychosocial factors among asymptomatic HIV-infected patients. Psychother Psychosom. 1999;68(1):31–8.PubMed
82.•
Logie C, Gadalla TM. Meta-analysis of health and demographic correlates of stigma towards people living with HIV. AIDS Care. 2009;21(6):742–53. This study analyzes with meta-analytic techniques the relationship between HIV-related stigma, the main psychosocial variable stressed by the literature, and demographical, social, physical and health characteristics of the patients.PubMed
83.
Lowther K, Selman L, Harding R, Higginson IJ. Experience of persistent psychological symptoms and perceived stigma among people with HIV on antiretroviral therapy (ART): a systematic review. Intern J Nurs Stud. 2014;51(8):1171–89.
84.
Nachega JB, Morroni C, Zuniga JM, Sherer R, Beyrer C, Solomon S, et al. HIV-related stigma, isolation, discrimination, and serostatus disclosure: a global survey of 2035 HIV-infected adults. J Int Assoc Physicians AIDS Care (Chic). 2012;11(3):172–8.
85.
Agrawal M, Srivastava K, Goyal S, Chaudhury S. Psychosocial correlates of human immunodeficiency virus infected patients. Ind Psychiatry J. 2012;21(1):55–60.PubMedCentralPubMed
86.
Stutterheim SE, Pryor JB, Bos AE, Hoogendijk R, Muris P, Schaalma HP. HIV-related stigma and psychological distress: the harmful effects of specific stigma manifestations in various social settings. AIDS. 2009;23(17):2353–7.PubMed
87.
Breet E, Kagee A, Seedat S. HIV-related stigma and symptoms of post-traumatic stress disorder and depression in HIV-infected individuals: does social support play a mediating or moderating role? AIDS Care. 2014;26(8):947–51.PubMed
88.
Benton TD. Depression and HIV/AIDS. Curr Psychiatry Rep. 2008;10(3):280–5.PubMed
89.
Kalichman SC, Rompa D, Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV/AIDS. J Nerv Ment Dis. 2000;188:662–70.PubMed
90.
Gibbie T, Mijch A, Ellen S, et al. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV Med. 2006;7:112–21.PubMed
91.
Castellon SA, Hardy DJ, Hinkin CH, Satz P, Stenquist PK, van Gorp WG, et al. Components of depression in HIV-1 infection: their differential relationship to neurocognitive performance. J Clin Exp Neuropsychol. 2006;28(3):420–37.PubMedCentralPubMed
92.
Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry. 2008;20:33–47.PubMed
93.
Wolff LC, Alvarado MR, Wolff RM. Depression in HIV infection: prevalence, risk factors and management. Rev Chil Infectol. 2010;27(1):65–74.
94.
Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev. 2010;12:67–75.PubMed
95.
Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick R. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2009;10:343–55.PubMedCentralPubMed
96.
97.
98.
Harrison DL, Miller MJ, Schmitt MR, Touchet BK. Variation in the probability of depression screening at community-based physician practice visit. Prim Care Companion J Clin Psychiatry. 2010;12(5):e1–8.
99.
Shacham E, Nurutdinova D, Satinarajana V, Stamm K, Overtone ET. Routine screening for depression: identifying a challenge for successful HIV care. AIDS Patients Care STDs. 2009;23(11):949–55.
100.•
Akena D, Joska J, Obuku EA, Amos T, Musisi S, Stein DJ. Comparison the accuracy of brief versus long depression screening instruments which have been validated in low and middle income countries: a systematic review. BMC Psychiatry. 2012;12:187. This recent review provides a comprehensive description of the available validated tools used to assess depression in HIV context, making a comparison between short and long instruments.PubMedCentralPubMed
101.
Mitchell AJ, Coyne JC. Do ultra-short screening instruments accurately detect depression in primary care? A pooled analysis and meta-analysis of 22 studies. Br J Gen Pract. 2007;57(535):144–51.PubMedCentralPubMed
102.
Cholera R, Gaynes BN, Pence BW, Bassett J, Qangule N, Macphail C, et al. Validity of the patient health questionnaire-9 to screen for depression in a high HIV burden primary healthcare clinic in Johannesburg, South Africa. J Affect Disord. 2014;167:160–6.PubMed
103.
Gordon S, Adul K, Kidd M, Smit J, Landon M, Dan S, et al. Validity of the K-10 in detecting DSM-IV-defined depression and anxiety disorders among HIV-infected individuals. AIDS Care. 2009;21:1163–8.
104.
Chishinga N, Kinyanda E, Weiss HA, Patel V, Ayles H, Seedat S. Validation of brief screening tools for depression and alcohol use disorders among TB and HIV patients in primary care in Zambia. BMC Pschiatra. 2011;11:75.
105.
Primeau MM, Avellaneda V, Musselman D, St Jean G, Illa L. Treatment of depression in individuals living with HIV/AIDS. Psychosomatics. 2013;54(4):336–44.PubMed
106.••
Spies G, Asmal L, Seedat S. Cognitive-behavioral interventions for mood and anxiety disorders in HIV: a systematic review. J Affect Disord. 2013;150:171–80. The present recent study reviews the existing literature on the use of CBI for depression in HIV-positive adults and to assess the effect size of these interventions.PubMed
107.•
Himelhoch S, Medoff DR, Oyeniyi G. Efficacy of group psychotherapy to reduce depressive symptoms among HIV-infected individuals: a systematic review and meta-analysis. AIDS Patient Care STDS. 2007;21(10):732–9. This is a systematic review and meta-analysis of double-blinded, randomized controlled trials to examine efficacy of group psychotherapy treatment among HIV infected with depressive symptoms.PubMed
108.
Hogagodu AR, Krishna M, Sundarachar R, Lepping P. Group psychotherapies for depression in persons with HIV: a systematic review. Indian J Psychiatry. 2013;55(4):323–30.
109.
Repetto MJ, Petitto JM. Psychopharmacology in HIV-infected patients. Psychosom Med. 2008;70(5):585–92.PubMed
110.
Blank MB, Himelhoch S, Walkup J, Eisenberg MM. Treatment considerations for HIV-infected individuals with severe mental illness. Curr HIV/AIDS Rep. 2013;10(4):371–9.PubMed
111.
Pence BW, Gaynes BN, Atashili J, O’Donnell JK, Kats D, Whetten K, et al. Feasibility, safety, acceptability, and preliminary efficacy of measurement-based care depression treatment for HIV patients in Bamenda, Cameroon. Ndumbe PAIDS Behav. 2014;18(6):1142–51.
112.
Pieper AA, Treisman GJ. Drug treatment of depression in HIV-positive patients: safety considerations. Drug Saf. 2005;28(9):753–62.PubMed
113.
Sin NL, DiMatteo MR. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. Ann Behav Med. 2014;47(3):259–69.PubMed
114.••
Hill L, Lee KC. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics. Ann Pharmacother. 2013;47(1):75–89. Reviewed the evidence for pharmacological treatment in the HIV context. In this recent review the authors analyze the evidence for pharmacological treatment in the HIV context, reporting also the data, very limited in current literature, regarding the use of antipsychotics.PubMed
115.•
Watson LC, Amick HR, Gaynes BN, Brownley KA, Thaker S, Viswanathan M, et al. Practice-based intervention concomitant depression and chronic medical conditions in the primary care setting: a systematic review and meta-analysis. J Prim Care Community Health. 2013;4(4):294–306. This recent study reviews in a systematic way and with meta-analytic techniques the effectiveness of practice-based interventions for improving depression and chronic medical outcomes in a medical setting.PubMed
116.
Power R, Gore-Felton C, Vorvick M, Israelski DM, Spiegel D. HIV: effectiveness of complementary and alternative medicine. Prim Care. 2002;29(2):361–78.PubMed
117.
Fulk LJ, Kane BE, Phillips KD, Bopp CM, Hand GA. Depression in HIV-infected patients: allopathic, complementary, and alternative treatments. J Psychosom Res. 2004;57(4):339–51.PubMed
118.
Ngô TL. Review of the effects of mindfulness meditation on mental and physical health and its mechanisms of action. Sante Ment Que. 2013;38(2):19–34.PubMed
Metadaten
Titel
Depression in HIV Infected Patients: a Review
verfasst von
Maria Giulia Nanni
Rosangela Caruso
Alex J. Mitchell
Elena Meggiolaro
Luigi Grassi
Publikationsdatum
01.01.2015
Verlag
Springer US
Erschienen in
Current Psychiatry Reports / Ausgabe 1/2015
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-014-0530-4

Weitere Artikel der Ausgabe 1/2015

Current Psychiatry Reports 1/2015 Zur Ausgabe

Psychiatric Diagnosis (MB First, Section Editor)

Melancholia and Catatonia: Disorders or Specifiers?

Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

The Bidirectional Relation Between Psychiatric Disorders With Selected Cardiovascular and Endocrinal Diseases: An Egyptian Perspective

Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

Psychopharmacology in Cancer

Personality Disorders (C Schmahl, Section Editor)

Personality Disorders in Older Adults: Emerging Research Issues

Anxiety Disorders (A Pelissolo, Section Editor)

d-Cycloserine Augmentation of Cognitive Behavioral Therapy for Anxiety Disorders: an Update

Anxiety Disorders (A Pelissolo, Section Editor)

Internet-Delivered Cognitive Behavior Therapy for Anxiety Disorders Is Here to Stay

Neu im Fachgebiet Psychiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise